PRTA
Prothena Corporation plc
NASDAQ: PRTA · HEALTHCARE · BIOTECHNOLOGY
$9.43
-4.97% today
Updated 2026-06-05
Market cap
$443.43M
P/E ratio
—
P/S ratio
7.65x
EPS (TTM)
$-2.81
Dividend yield
—
52W range
$5 – $12
Volume
0.5M
WallStSmart proprietary scores
58
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+6.0
Quality
B4.0
Profitability
C6.0
Valuation
B1/9
Piotroski F-Score
Weak
-3.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$21.40
+126.94%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy1 Buy2 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $28.88M — positive
+ Revenue growth 1,706.00% QoQ
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -3.13 — distress zone
- Thin margins at -260.90%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $53.91M | $91.37M | $135.16M | $9.68M | $57.94M |
| Net income | $-116.95M | $-147.03M | $-122.31M | $-244.09M | $32.72M |
| EPS | — | — | — | — | $-2.81 |
| Free cash flow | $-109.28M | $-136.72M | $-150.35M | $-163.72M | $28.88M |
| Profit margin | -216.95% | -160.91% | -90.49% | -2,520.57% | -260.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-04 | SCULLY, WILLIAM P | Buy | 50,000 | $9.31 |
| 2026-06-02 | SCULLY, WILLIAM P | Buy | 50,000 | $9.43 |
| 2026-05-22 | SCULLY, WILLIAM P | Buy | 100,000 | $9.81 |
Peer comparison
Smart narrative
Prothena Corporation plc trades at $9.43. Our Smart Value Score of 58/100 indicates the stock is fair. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -3.13, it sits in the distress. TTM revenue stands at $57.94M. with profit margins at -260.90%.
Frequently asked questions
What is Prothena Corporation plc's stock price?
Prothena Corporation plc (PRTA) trades at $9.43, on a P/S of 7.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Prothena Corporation plc overvalued?
Prothena Corporation plc carries a Smart Value Score of 58/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Prothena Corporation plc (PRTA)?
The 12-month analyst consensus target is $21.40, about 126.9% above the current $9.43. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Prothena Corporation plc's revenue?
Prothena Corporation plc's trailing twelve-month revenue is $57.94M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Prothena Corporation plc's Altman Z-Score is -3.13, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.65x
ROE-48.36%
Beta-0.32
50D MA$10.13
200D MA$9.64
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.5M
Performance
1 week+0.00%
1 month-8.44%
3 months-4.56%
YTD-7.96%
1 year—
3 years—
5 years—